Riding the Waves of HIMS Volatility: How Traders Are Positioning
Telehealth darling sees wild swings — here’s how opportunistic investors are trying to profit
Hims & Hers Health (ticker: HIMS), listed on the NYSE in the telehealth / digital health sector, has become one of the most volatile and talked-about stocks in recent weeks. Its sharp price swings are drawing the attention of traders across Wall Street and retail platforms alike. With momentum, regulatory scrutiny, and huge upside and downside potential in play, HIMS stands out as a high-risk, high-reward name for investors who thrive on volatility.
Currently, HIMS trades between $52 and $58, well below its 52-week high of $72.98. The company’s public float is limited, amplifying the impact of any buying or selling pressure. Its beta and implied volatility levels suggest that the market expects continued turbulence. The stock’s implied volatility remains slightly above its 20-day historical volatility, signaling that options traders are pricing in more wild moves ahead.
Earlier this year, HIMS stock surged over 100% year-to-date, as investors piled in on the company’s expansion into the weight-loss and telehealth niche. The firm broadened its offerings by adding men’s health services, including testosterone replacement therapy, complementing its existing segments such as hair loss treatments, dermatology, and general wellness. These moves fueled strong momentum and bullish options activity, as retail traders speculated on further gains and institutions noticed rising volume.
However, optimism turned into caution after Novo Nordisk abruptly terminated its partnership with Hims, alleging that the company was marketing unapproved compounded versions of Wegovy, a popular weight-loss drug. The news triggered a massive 35% plunge in HIMS shares in a single trading session, sending shockwaves through the telehealth sector. The fallout highlighted regulatory risks and raised new questions about Hims’ marketing practices and long-term strategy.
Analysts remain divided on the outlook for the stock. Some believe HIMS is overextended, pointing to high valuation multiples — with a forward P/E ratio hovering around 70–80x — and suggesting that the company could be vulnerable if growth slows or regulatory oversight increases. Others see opportunity in the chaos, arguing that HIMS embodies the modern “story stock”, where derivatives traders and momentum investors can extract outsized returns if they time their entries and exits correctly.
Among active traders, one popular approach to profit from volatility is selling cash-secured puts below current prices. For example, selling a $50 strike put could yield a hefty premium, allowing traders to benefit from HIMS holding its ground. If the stock dips below $50, they’d get assigned shares at a discount, potentially setting up for a profitable rebound later. However, this strategy carries significant risk — a deeper decline could translate into large paper losses for anyone caught unhedged.
Volatility trading is not for everyone. If HIMS collapses due to negative catalysts, such as fresh regulatory actions, disappointing financials, or a broader market selloff, the downside can be brutal. Successful traders in this space emphasize discipline, tight risk controls, and quick decision-making as non-negotiables.
Looking ahead, key events for Hims & Hers include its next earnings release, updated guidance, and any new statements from the FDA or other regulators regarding drug compounding and marketing practices. If the company navigates these hurdles effectively and continues expanding into new health verticals, long-term investors could view today’s volatility as an opportunity in disguise. But if management fails to restore confidence or faces additional legal scrutiny, the stock could face another sharp leg down.
In simple terms, HIMS is not for the faint of heart. It’s a stock where volatility is both the risk and the opportunity. For savvy traders, it’s a playground full of potential — but for long-term investors without strong risk appetite, it’s a reminder that even the hottest telehealth names can cool down fast.